CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Alzheimer's Disease
Interventions
GENETIC

CERE-110: Adeno-Associated Virus Delivery of NGF

CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg

Trial Locations (2)

60612

Rush University Medical Center, Chicago

92037

University of California San Diego, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ceregene

INDUSTRY

lead

Sangamo Therapeutics

INDUSTRY